解市 | 美團點評-W意外落選恒指,小米、藥明、阿里入選後走勢分化
恒指公司上週五港股市後宣佈,阿里巴巴-SW、小米集團-W和藥明生物將被納入恒生指數;信和置業、中國旺旺、中國神華將被剔除;調整將於9月7日生效。此前的預測大熱門美團點評-W意外落選。
消息落地後的首日交易日(截至9:57分):小米集團-W升6%、藥明生物高開低走升2.35%、阿里巴巴-SW跌1.54%,落選的美團點評-W大幅低開後反彈跌1%。
阿里巴巴-SW今日走勢未受利好提振,或因一則偏利空的外媒報導。
據《路透》此前報導,美國總統特朗普表示,會在禁絕TikTok後,會向其他中國企業施壓,當被問及會否包括阿里巴巴(09988.HK),特朗普表示正檢視其他針對中國企業的事情。
機構:美團的納入只是一個時間的問題
銀河-聯昌稱,藥明生物取代美團點評進入恒生指數是一大意外,不過預計美團的納入只是一個時間的問題。
中金公司稱,阿里巴巴等互聯網龍頭入選恒生指數和恒生國企指數,將使得新經濟佔比提升,有利提高港股市場中長期吸引力。
銀河-聯昌分析師Wong Chi Man等在報告中指出,預計進入恒指後, 阿里巴巴、小米集團和藥明生物將分別有13.4億、6.9億和4.7億美元的被動資金流入。
藥明生物將受到明顯提振,因有較少的投資者預期其會進入恒指。
美團點評未能進入恒指可能的原因包括去年為公司第一年盈利,考察週期短;恒生指數公司不想一次性納入三家互聯網巨頭。
中金分析師王漢鋒等 在報告中指出,恒生指數中,阿里巴巴、小米集團和藥明生物預計將出現9.9億、5.1億、3.5億美元的被動資金流入;被動資金流出最大的騰 訊、滙豐、建行和神華預計將出現合計約6.5億美元左右的資金流出
調整後,恒生指數中的信息技術權重將從1.7%跳升至4.2%,國企指數中資訊技術權重將從1.8%升至3.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.